Company: APM
Filing Date: 2025-07-15
Form Type: DRS
Source: 0001213900-25-063899
Chunk: 80

Company: Aptorum Group Ltd
Filing Date: 2025-07-15
Form: DRS
Chunk 80
---
 claims for monetary damages or other
penalties under that agreement. Such an occurrence would diminish or eliminate the value of that project to our Company, even if we are
able to negotiate new or reinstated agreements, which may have less favorable terms. Depending on the importance of the IP and the related
project, any such development could have a material adverse effect on our competitive position, business, financial conditions, results
of operations, and prospects.

Moreover, disputes may arise
regarding intellectual property subject to a licensing agreement, including:

| ● | the scope of rights granted under the license agreement and other interpretation-related issues;                                                   |
| ● | the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement; |

| ● | the sublicensing of patent and other rights under our collaborative development relationships;                 |
| ● | our diligence obligations under the license agreement and what activities satisfy those diligence obligations; |

| ● | the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners; and |
| ● | the priority of invention of patented technology.                                                                                                                         |

<div align='center'>36</div>

In addition, the agreements
under which we currently license intellectual property or technology from other parties are complex, and certain provisions in such agreements
may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow
what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our
financial or other obligations under the relevant agreement, either of which (depending on the importance of the IP and the related project)
could have a material adverse effect on our business, financial condition, results of operations, and prospects. Moreover, if disputes
over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangement for a project
on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected drug and diagnostics technology
candidates, which could have a material adverse effect on our business, financial conditions, results of operations, and prospects.

We may not have complete control of the preparation, filing and prosecution of patent applications, or to maintain patents, licensed by us from other parties.

The Company has in-licensed,
and may in the future in-license patents owned or controlled by others for our use as part of our development plans. We also may out-license
or sublicense